SB2770, titled the “Share the Savings with Seniors Act,” would amend Medicare Part D to change how cost-sharing is calculated for certain chronic care drugs beginning with plan years on or after January 1, 2027. The bill requires that, for specified chronic care drugs, cost-sharing below the deductible may not exceed the drug’s net price, and that coinsurance above the deductible and below the out-of-pocket threshold be based on a percentage of the drug’s net price. It also creates an exception for plans that use fixed copayments not tied to drug prices or benchmark costs.
The bill defines “chronic care drug” by reference to specific USP Medicare Model Guidelines categories, including drugs used for diabetes, respiratory conditions, anticoagulants, and cardiovascular therapies, and allows the Secretary or USP to identify successor categories. It also defines “net price” as the negotiated price minus manufacturer concessions not already reflected in that price. In addition, the bill makes a conforming change to the low-income subsidy rules so that, for 2027 and later, copayments for these chronic drugs cannot exceed the cost-sharing applicable under the beneficiary’s Part D or MA-PD plan. The Secretary of Health and Human Services would be directed to implement the changes initially through interim final regulations.
Impact
The bill would amend sections 1860D-2 and 1860D-14 of the Social Security Act, affecting Medicare Part D plan design, beneficiary cost-sharing, and low-income subsidy calculations. It would require Part D sponsors and Medicare Advantage prescription drug plans to align cost-sharing for covered chronic care drugs with net drug prices, which could reduce out-of-pocket costs for beneficiaries using long-term maintenance medications and alter how plans structure formularies and pricing arrangements. It would also require HHS to issue interim final regulations to implement the changes.
Sentiment
The available context suggests generally favorable intent, as the bill is framed as a senior-focused savings measure and was introduced by a bipartisan group of senators. The title and substance indicate a policy goal of lowering prescription drug costs for Medicare beneficiaries with chronic conditions. No committee debate or recorded votes are provided, so there is no evidence of formal opposition or support beyond the bill’s sponsorship and referral status.
Contention
The main potential points of contention are likely to be the requirement that cost-sharing be tied to net price, the treatment of manufacturer rebates and concessions, and the effect on Part D plan pricing and benefit design. Plans and pharmacy benefit managers could view the net-price-based approach as administratively complex or disruptive, while beneficiary advocates would likely support the lower cost-sharing. Another possible issue is the bill’s limited scope: it applies only to specified chronic care drug categories and includes an exception for certain fixed-copayment structures, which may raise questions about consistency and coverage boundaries.